Genmab

	21/5 13:30 af Bulder	Svært at sige. Sagen kan godt være på CHMP's dagsorden, uden at der bliver besluttet noget. Måske sender de sagen videre til PRAC (safety). Og så kan der gå lang tid.
	21/5 13:22 af lahn1	Generelt, hvis man er på EMA’s agenda f.eks i denne uge/md. hvornår kan man så regne med at høre nyt når det handler om godkendelse eller ej ?
	21/5 13:13 af E L	disclaimer; i am NOT a doctor ;-)
	21/5 13:13 af E L	my gutfeel is that most epco response also are CMR, but if not ALL of them are, or if the trial criteria were not CMR they can not call it that
	21/5 13:11 af Bulder	Yes, I assume that CR vs CMR is of minor importance then.
	21/5 13:11 af E L	they have strict criteria for it in the Ph3 ' Response is determined by the Lugano criteria and LYRIC'
	21/5 13:10 af E L	you can rest assured that response rate classification is very strict and will be checked stringently by authorities
	21/5 13:10 af Bulder	so detectable vs measurable?
	21/5 13:08 af E L	In the Ph3 it already says 'Patients must have detectable disease by PET scan and measurable by CT scan or MRI'
	21/5 13:07 af E L	For example, if you look at Main Inclusion Criteria Escalation Part for Epco Ph I/II trial, it says ' Patients must have measurable disease by CT, MRI or PET-CT scan'
	21/5 13:06 af E L	i am not sure; it probably has to do with how the trials are set up; CT scan is probably a lower entry bar, that does not necessarily mean these patients did not get PET in most of the hospitals
	21/5 12:58 af Bulder	And CT is x-ray. Can x-ray detect cancer in liquids?
	21/5 12:52 af Bulder	But it sounds like PET is used for cancer, so why CT?
	21/5 12:48 af E L	(link)
	21/5 12:46 af E L	yes, PET is more reliable
	21/5 12:46 af Raun	TA kyndige?..... Hvis jeg har forstået det korrekt, har Genmab igennem det seneste stykke tid, været i teknisk nedtrend..... Hvis aktien holder sit nuværende niveau resten af dagen og forhåbentlig også mandag. - Vil aktien da ikke være inde i sin stigende trendkanal igen?
	21/5 12:45 af Bulder	Could be. They say PET every time they say CMR. Is the one more reliable than the other?
	21/5 12:43 af E L	could it be that CMR is according to PET scan, and CR is CT scan, but i am not sure on this
	21/5 12:33 af Bulder	Peter, hvordan udleder du af artiklen, hvad forskellen er?
	21/5 12:29 af Helge Larsen/PI-redaktør	Aktier/middag: Rekord i C25 og fem eliteaktier (link)
	21/5 12:07 af peter12	Google siger (link)
	21/5 10:35 af Bulder	I glofi-abstractet opererer man med komplet metabolisk respons. I epco bruger man komplet respons. Jeg er ikke lykkedes med at finde en forklaring på forskellen. Nogen?
	21/5 08:45 af fizz	Jeg mener de fik tildelt warrents i den amerikanske notering. Det kan måske være disse?
	21/5 07:59 af Plimsoller	God morgen :-)

	21/5 07:21 af Helge Larsen/PI-redaktør	Fredagens aviser med Rockwool, Maersk Drilling og Jeudan (link)
	21/5 07:21 af Helge Larsen/PI-redaktør	Genmab: Udviklingschef sælger aktier for 283.118 dollar (link)
	21/5 07:19 af Helge Larsen/PI-redaktør	Asien: Tokyo trækker op i blandede markeder - NY (link)
	21/5 07:19 af Helge Larsen/PI-redaktør	God morgen. :-)
	20/5 20:52 af bibob	Numab to Challenge Genmab. (link)
	20/5 19:00 af Bulder	Den afsluttende stigning satte ind præcis kl 15.30. Altså igen sammenfaldende med åbning i us.
	20/5 17:58 af AaBforever	Pt omregnet 2375
	20/5 17:52 af Darvin	Og - de er ikke mindre glade for Genmab i dag derovre :-)
	20/5 16:30 af Bulder	US har helt skiftet farve. NBI mørkegrøn.
	20/5 15:48 af Bulder	Og de behøver ikke vise coronapas for at komme ind.
	20/5 14:47 af E L	Daratumumab and Pomalidomide in Previously Treated Patients With AL Amyloidosis (DarPAL) - New trial (link)
	20/5 14:46 af E L	or like AbbVie for Lemzoparlimab , whatever that is, never heard of it, New trial - (link)
	20/5 14:44 af E L	we'll also see more extensions being requested by other companies , like Amgen for Carfilzomib, just as JNJ included Revlimid in many of the extensions
	20/5 14:20 af Bulder	I assume "a number of" is more than 1.
	20/5 14:19 af Bulder	Winkel didn't answer that Q, but on the other hand he said "We fully expect a number of new label extensions to be executed in the coming time."
	20/5 14:18 af Bulder	I wonder if they'll wait for that study before they file dara as maintenance, or if Cass part 2 is enough.
	20/5 13:09 af E L	and one more maintenance on the Auriga trial, Dara vs SOC (link)
	20/5 13:07 af E L	another maintenance abstract - Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA (link)
	20/5 12:07 af E L	no, maybe we'll hear a bit more in June; this is data from December with only 'Median (range) treatment duration was 22 (1–178) days'
	20/5 11:46 af Bulder	Well, response not impressive. But dont know what to expect in these indications.
	20/5 11:22 af E L	ASCO : A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors. (link)
	20/5 10:28 af Sukkeralf	Nice work diggin´ good stuff up :-)
	20/5 10:24 af E L	;-) one more then - Biotech ASCO: Johnson & Johnson's bispecific lung cancer combo shows promise as Tagrisso backup, but the Big Pharma wants more (link)
	20/5 10:09 af Bulder	thx E L. Easier to understand ;-)
	20/5 10:00 af E L	and a bit more on amivantamab (link)
	20/5 09:52 af E L	JNJ press release - Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer - (link)